136
Participants
Start Date
December 12, 2023
Primary Completion Date
November 1, 2024
Study Completion Date
November 1, 2024
Placebo
S.C. Injection
XXB750 Low dose
S.C. Injection
XXB750 Medium Dose
S.C. Injection
XXB750 High Dose
S.C. Injection
Sacubitril/valsartan
Tablet
Novartis Investigative Site, Budapest
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Kyustendil
Novartis Investigative Site, Plovdiv
Novartis Investigative Site, Gabrovo
Novartis Investigative Site, Pleven
Novartis Investigative Site, Balatonfüred
Novartis Investigative Site, Varna
Novartis Investigative Site, Berlin
Novartis Investigative Site, Santiago de Compostela
Novartis Investigative Site, Milan
Anderson Medical Research, Ft. Washington
Novartis Investigative Site, Huelva
Dominion Medical Associates, Richmond
Novartis Investigative Site, Kiel
Novartis Investigative Site, Brescia
Novartis Investigative Site, Papenburg
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Málaga
American Clinical Trials, Acworth
Inpatient Research Clinical LLC, Miami Lakes
Novartis Investigative Site, Pordenone
Cardiology Partners Clinical Research Institute, Wellington
Novartis Investigative Site, Trieste
Nature Coast Clinical Research LLC, Inverness
Novartis Investigative Site, Las Palmas de Gran Canaria
Heart Center Research Llc, Huntsville
SEC Clinical Research, Dothan
Tennessee Center For Clinical Trials, Tullahoma
Novartis Investigative Site, Taichung
The Research Group, Lexington
Aultman Hospital, Canton
NexGen Research, Lima
Novartis Investigative Site, Gladbeck
Novartis Investigative Site, Valencia
Novartis Investigative Site, Valencia
Revival Research Institute, Troy
Novartis Investigative Site, Cologne
Novartis Investigative Site, Ludwigshafen
Heart Clinic of Hammond, Hammond
Novartis Investigative Site, Schwäbisch Hall
Novartis Investigative Site, Messina
Novartis Investigative Site, Bikaner
Novartis Investigative Site, Belagavi
Novartis Investigative Site, Xian
Novartis Investigative Site, Blagoevgrad
Novartis Investigative Site, Roma
Novartis Investigative Site, Roma
Novartis Investigative Site, Maebashi
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Sagamihara
Novartis Investigative Site, Matsumoto
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Vila Nova de Gaia
Novartis Investigative Site, Košice
Novartis Investigative Site, Martin
Novartis Investigative Site, Svidník
Novartis Investigative Site, Bardejov
Novartis Investigative Site, Nitra
Novartis Investigative Site, Prešov
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY